Institute for Cancer Research

 

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.

The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.

Gunnar Sæter<br>Scientific director
Gunnar Sæter
Scientific director

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
 2016  so far  
2015 236  
2014 176  
2013 197 27
2012 175 18
2011 201 22

Annual report 2014 (pdf format)

 

Latest news

Ragnhild A. Lothe and Michael Bretthauer substantially supported by FRIPRO

 
Lothe and Bretthauer
Lothe and Bretthauer

The Research Council of Norway and Norway’s research institutions are providing a total of NOK 1 billion to 46 FRIPRO Toppforsk projects (FRIPRO - "Frie prosjektmidler"). Each project will receive NOK 15–25 million over a four-to-five-year period.
FRIPRO is an open competitive arena for all research areas and disciplines, where there are no thematic guidelines and no requirements relating to the applicability or immediate utility of the research. The competition in FRIPRO is tough, and only the best researchers with particularly good projects and very well-written proposals have a chance at succeeding.
University of Oslo and Oslo University Hospital based research groups led by Ragnhild A. Lothe from the Department of Molecular Oncology and Michael Bretthauer from the Department of Transplantation Medicine are among the successful applicants. 

 
 

Camilla Raiborg's work presented in popularised form on forskning.no:

Filming live cancer cells

 
Camilla Raiborg (photo: Nina Marie Pedersen)
Camilla Raiborg (photo: Nina Marie Pedersen)

The ongoing scientific activities of Camilla Raiborg from Harald Stenmark's group at the Department of Molecular Cell Biology have recently been presented on the major Norwegian popular science web site forskning.no, as well as on the home page of the Norwegian Cancer Society. Raiborg is heading the project group "Protein dynamics in tumor suppressor pathways".

 
 

Lorenz et al. published an extensive study investigating the genomic chaos in osteosarcoma

 
Susanne Lorenz
Susanne Lorenz

Susanne Lorenz has together with her colleagues at the Department for Tumor Biology and the Genomics Core Facility recently published an extensive genomic study of osteosarcoma in Oncotarget (journal impact factor 6.4). This study combined whole genome and transcriptome sequencing to unscramble the genomic chaos and its consequences.

 
 

Symposium, Oslo, May 18-20, 2016

Personalized Cancer Care

 

What have we achieved since 2012 in risk prediction, early diagnosis, progression, and therapy?

This Symposium is part of an annual series that Prof. Enrico Mihich has been organizing in collaboration with Hans-Peter Huber and Kurt S. Zänker at the Fritz Bender Foundation, Munich, Germany and a host institution.

In 2012 this symposium took place in Oslo, Norway with the Institute for Cancer Research at the Norwegian Radium Hospital Oslo University Hospital and the Radium Hospital Foundation as hosts. It was decided at that meeting that a second symposium with the same program and speakers should take place 3-4 years later with the focus on what have we achieved since 2012. Hence the follow-up meeting will take place in Oslo in May 2016.

The symposium is now open for registration and abstract submission.

 
 

New PhD Andreas Hoff publishes testis cancer fusion genes in Cancer Research

 
Andreas M. Hoff
Andreas M. Hoff

Andreas Midbøe Hoff, who recently defended his PhD thesis, has together with colleagues at Department of Molecular Oncology discovered novel fusion genes in testicular germ cell tumours. The results are published in the current issue of Cancer Research (journal impact factor 9.28)

 

 
 

Åslaug Helland’s research on lung cancer presented by the Norwegian Cancer Society

 
Åslaug Helland (photo: Per Marius Didriksen)
Åslaug Helland (photo: Per Marius Didriksen)

Åslaug Helland and coworkers have been part of a study where lung cancer tumours have been reduced in size after giving the patients drugs previously used in treatment of malignant melanomas. These studies have been performed due to certain similarities between lung cancer and melanoma cells. The research is part of an international clinical study where in total 40 lung cancer patients have been given the drugs dabrafenib and trametinib.